89zr-trastuzumab pet supports clinical decision making in breast cancer patients, when her2 status cannot be determined by standard work up

HIGHLIGHTS

• who: Frederike Bensch from the Department of Medical Oncology, University of, GZ, The Netherlands have published the article: 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up, in the Journal: (JOURNAL)
• what: The authors report SUVmax for tumour lesions and SUVmean for normal organ tracer uptake.
• future: The impact of CTC HER2 status on clinical decision making is unclear from this study as the result was not reported to the referring physician.

SUMMARY

HER2-positivity, reported in . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.